Hong Kong stock biopharmaceutical sector warms up, innovative drug research and development enters a period of harvest.

In the first half of this year, the biopharmaceutical sector of the Hong Kong stock market has been achieving remarkable results, with many listed companies seeing the fruits of their previous research and development efforts, injecting new impetus into their performance growth and driving related concept indexes to continue rising. According to Wind data, about 110 Hong Kong biopharmaceutical companies have released their interim financial reports as of June 30. Among them, nearly 70 companies have seen year-on-year growth in operating income, with nearly 10 companies achieving revenue growth rates exceeding 100%; nearly 80 companies have shown positive performance in their net profit attributable to shareholders, with nearly 40 companies achieving year-on-year growth in net profit attributable to shareholders, about 10 companies turning losses into profits, and nearly 30 companies reducing year-on-year losses. As of September 3, the Hang Seng Innovative Drug Index has risen by 117.55% year-to-date, indicating that investor confidence in Hong Kong's biopharmaceutical sector is rapidly recovering and improving. Guoyuan Securities mentioned in their research report that China's innovative drugs are entering a phase of realizing achievements, with significant progress in research and development catalyzing further growth, and they continue to have a positive outlook on the sector's performance in the second half of the year.